MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns

  • MaxCyte Inc MXCT appointed Ron Holtz, current Senior Vice President, and Chief Accounting Officer, as the Interim Chief Financial Officer.
  • The change comes as Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. 
  • MaxCyte also expects Q1 FY22 sales of at least $11.0 million, versus the consensus of $8.46 million and $6.5 million in Q1 FY21.
  • Core business revenue is expected to be at least $9.0 million, and SPL Program-related revenue is expected to be $2.0 million. 
  • The Company has engaged executive search firm Korn Ferry to lead a search for a new Chief Financial Officer.
  • Price Action: MXCT shares closed 1.92% higher at $5.85 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapManagementGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!